Krysof, Kiplit or Kiplev Could Be Candidate Names For Actelion Tezosentan
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Actelion could be considering Krysof, Kiplit or Kipliv as the tradename for its cardiovascular agent tezosentan. The company submitted the names to the Patent and Trademark Office for a therapy to treat heart failure.